Navigation Links
Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
Date:5/15/2008

ue to be studied in the treatment and prevention of cancer, and the NCI supported the continuation of the trials, encouraging investigators to weigh the risks and benefits of the drug for their specific clinical setting.

After adding stringent guidelines to further reduce the cardiac risk to patients, the M. D. Anderson investigators then reapplied to the institution's Institutional Review Board to reactivate the trial. The study reopened in May 2005.

Kim noted that there were no adverse cardiac events in the M. D. Anderson trial. Three patients experienced grade three toxicities on the higher dose of the drug which were not cardiac related.

Lung cancer is the leading cause of cancer death in the United States, according to the American Cancer Society. In 2008, approximately 215,000 people will be diagnosed with lung cancer and approximately 114,000 people will die from the disease.

The study was funded by a five-year, $10 million POI lung grant, awarded in 2001 by the NCI to a multi-disciplinary team headed by Waun Ki Hong, M.D., head of the Division of Cancer Medicine. M. D. Anderson has been a leader in chemoprevention since the early 1990s, when Hong was the first to demonstrate that retinoids can reverse oral leukoplakia, a premalignant condition that often leads to cancer, and that 13-cis retinoic acid can prevent secondary primary tumors among patients with head and neck cancers.

"Lung cancer remains a lethal and stubborn disease with tobacco as the leading culprit for this killer," said Hong. "The Celebrex findings are exciting for the entire field of lung cancer chemoprevention."


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Celebrex, Naproxen Wont Prevent Mental Decline
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex-Lipitor combo may halt prostate cancer
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Kids Growing Up on Grown Up Drugs: New Research Shows Treatments for Adult Ailments Rapidly Rising in Children
6. Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File
7. New Survey Shows Americans Value Oral Health But Knowledge Gap Remains
8. Research shows HPV testing offers women protection for twice as long as smear testing
9. Study shows that prostate cancer increases the risk of bone fracture
10. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
11. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
(Date:3/6/2015)... 2015 Further solidifying their position as ... Associates announced today that the company has earned Inavero’s ... Best of Staffing Talent Award five years in a ... Staffing Talent Diamond winners are proven industry leaders in ... by the individuals they have helped find temporary and ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... Covington, La (PRWEB) March 06, 2015 ... reduced function despite medical therapy. If you (or someone ... due to knee osteoarthritis, you may be interested in ... with Covington Orthopedic announced today that he is one ... from Cytori Therapeutics to begin enrolling subjects as part ...
(Date:3/6/2015)... Truly Nolen, the largest family-owned pest control company in ... their first independently-owned and operated franchise in North Carolina, ... – Rock Hill, SC area. The ribbon cutting ceremony ... location. , The Truly Nolen Carolina team ... pest control industry. Locally owned and operated by local ...
(Date:3/6/2015)... Yisrayl Hawkins, Pastor and Overseer of The House ... publication explaining how micro-kingdoms keep the earth and everything ... “Microorganisms Do Much More Than You Think” is a ... and designed to keep all things functioning properly. He ... of these micro-kingdom, but does not realize their full ...
Breaking Medicine News(10 mins):Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2
... Md., Aug. 12 The third annual Psoriasis Cure Now ... a theme of helping psoriasis patients connect with one another. ... patients to resist the social isolation that often results from ... with psoriasis and psoriatic arthritis to provide mutual support and ...
... French . , Montreal, August 12, 2009 Sounds ... according to a new Canadian study. In the online edition of ... PNAS ), scientists from the Universit de Montral and the Montreal ... in the brain allows people to distinguish between different types of ...
... ... of device, new trials , ... San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage ... permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials ...
... , , Milestone shows ... shows how much the culture has changed when reporting medical events , ... Safety Authority has collected over one million reports from Pennsylvania healthcare facilities ... events that did not cause harm to the patient. , , ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that ... correct the ownership of its intellectual property (IP) rights. ... five (5) issued patents, HTDS finds that the Company ...
... ROCHESTER, N.Y., Aug. 12 VirtualScopics, Inc. (Nasdaq: VSCP ... financial results for the quarter and six months ended June 30, 2009. ... Revenues for the second quarter of 2009 increased 47% to $2.5 million, compared ... Gross profit for the second quarter of 2009 increased 96% to $1.4 ...
Cached Medicine News:Health News:Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 2Health News:Human mind: Sound and vision wired through same 'black box' 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 2Health News:OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 2Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 3Health News:Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 4Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 2Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 3Health News:Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 2Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 3Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 4Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 5Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 6Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 7Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 8Health News:VirtualScopics, Inc. Reports a Record Breaking Quarter 9
(Date:3/6/2015)... , March 6, 2015 The ... U.S. Food and Drug Administration (FDA) on its approval ... in the U.S. market. Approval of Novartis, Zarxio (filgrastim-sndz), ... the January recommendation by an FDA advisory panel that ... the reference product is approved. "The approval ...
(Date:3/6/2015)... 2015  Palatin Technologies, Inc. (NYSE MKT: PTN) announced today ... Annual ROTH Conference on Wednesday, March 11, 2015, at 10:30 ... Ritz Carlton Laguna Niguel in Dana Point, CA. ... President and Chief Executive Officer of Palatin Technologies, will provide ... About Palatin Technologies, Inc. Palatin Technologies, ...
(Date:3/6/2015)... March 6, 2015  The onset of puberty can make ... as clumsier, and thus more inclined toward a variety of ... while the body,s center of gravity is altered. It,s a ... grow more quickly than the rest of the body and, ... in single year. And while these sudden changes are a ...
Breaking Medicine Technology:ASBM Commends FDA for Approval, Clear Naming of First Biosimilar 2Puberty can result in variety of athletic injuries 2
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... will present at the Sixth Annual JMP Securities Healthcare Conference ...  The conference will be held at the St. Regis hotel ... the presentation can be accessed through the investor relations section ...
... Pa., Sept. 13, 2011 ViroPharma Incorporated (Nasdaq: ... HALO ) announced today  that ViroPharma ... to evaluate the safety, and pharmacokinetics and pharmacodynamics ... [human)] in combination with Halozyme,s Enhanze™ technology, a ...
Cached Medicine Technology:Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 2ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 3ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 4ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 5ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 6ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20) 7
20 GA TITANIUM RETINAL FORCEPS...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Permits rotation of the globe during examination. Overall length,123mm....
Medicine Products: